Features of a necrotic and inflammatory process in different forms of nonalcoholic fatty liver disease


Cite item

Full Text

Abstract

Aim. To identify the features of development of a necrotic and inflammatory process in different forms of nonalcoholic fatty liver disease (NAFLD), by comparatively analyzing a full set of clinical and laboratory parameters, including the cytokine status and the expression level of enzyme genes controlling the apoptosis of peripheral leukocytes. Subjects and methods 86 patients with NAFLD, including 8 (9.3%) with hepatic steatosis (HS), 70 (81.4%) with nonalcoholic steatohepatitis (NASH), 40, 19, and 11 with mild, moderate, and high disease activity, respectively, and 8 (9.3%) with liver cirrhosis (LC), were examined. A control group consisted of 34 healthy donors. Clinical and biochemical blood indices, cytokine profile, and the level of caspase gene transcripts in the peripheral blood leukocytes (PBL) were estimated. Results. As compared to the controls, the patients with HS had higher tumor necrosis factor-α (TNF-α) and interleukin 6 (IL-6) levels and lower caspase 3, 6, and 8 mRNA in PBL. The concentration of IL-10 in NASH was higher than that in steatosis and positively correlated with the level of proinflammatory cytokines. The levels of TNF-α and IL6 were higher in the patients with NASH than in the controls. Those of C-reactive protein, γ-globulin, IL-6, and cytokeratin-18 fragment increased with the progression of NASH. In the latter, the transcriptional activity of caspase-3 gene decreased relative to the reference value and negatively correlated with the level of proinflammatory cytokines. In the patients with LC, the gene expression profile of caspases in PBL was similar to that in the control group; the level of IL-6 was higher than that in steatosis and NASH, that of IL-1β was higher than in HS and positively correlated the concentration of IL-6 and the activity of alanine aminotransferase and aspartate aminotransferase. Conclusion. The features of a necrotic and inflammatory process were identified in different forms of NAFLD. When the latter progressed, the cytokine profile and gene expression levels of caspases in PBL altered along with a change in the general clinical picture.

About the authors

I V Kurbatova

Институт биологии Карельского научного центра РАН

Петрозаводск, Россия

O P Dudanova

Петрозаводский государственный университет

Петрозаводск, Россия

References

  1. Stefan N, Kantartzis K, Häring HU. Causes and metabolic consequences of Fatty liver. Endocrine Reviews. 2008;29(7):939-960. doi: 10.1210/er.2008-0009
  2. Драпкина О.М., Деева Т.А., Волкова Н.П., Ивашкин В.Т. Современные подходы к диагностике и лечению неалкогольной жировой болезни печени. Терапевтический архив. 2014;86(10):116-123.
  3. Беспалова И.Д., Рязанцева Н.В., Калюжин В.В., Афанасьева Д.С., Мурашев Б.Ю., Осихов И.А. Системное воспаление в патогенезе метаболического синдрома и ассоциированных с ним заболеваний Сибирский медицинский журнал. 2013;(2):5-9.
  4. Braunersreuther V, Viviani GL, Mach F, Montecucco F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. World Journal of Gastroenterology. 2012;18(8):727-735. doi: 10.3748/wjg.v18.i8.727
  5. Стилиди Е.И. Роль фактора некроза опухоли альфа и интерлейкина-6 в патогенезе неалкогольного стеатогепатита. Крымский терапевтический журнал. 2012;(1):91-98.
  6. Guicciardi ME, Gores GJ. Apoptosis as a mechanism for liver disease progression. Seminars in Liver Disease. 2010;30(4):402-410. doi: 10.1055/s-0030-1267540
  7. Copaci I, Micu L, Voiculescu M. The role of cytokines in non-alcoholic steatohepatitis. A review. Journal of Gastrointestinal and Liver Diseases. 2006;15(4):363-373.
  8. Pаr A, Pаr G. Liver fibrosis: patho-physiology, diagnosis and treatment. Orvosi Hetilap. 2005;146(1):3-13.
  9. Звягинцева Т.Д., Глущенко С.В. Липотоксический стресс и провоспалительные цитокины как факторы развития неалкогольного стеатогепатита. Научные ведомости. Серия Медицина. Фармация. 2014;18(189):46-49.
  10. Сивкова А.А., Ларева Н.В., Лузина Е.В. Патогенетическое значение цитокинов в формировании и прогрессировании неалкогольной жировой болезни печени. Сибирский медицинский журнал. 2011;(4):56-58.
  11. Brunt EM., Janney CG., Di isceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. The American Journal of Gastroenterology. 1999;94(9):2467-2474. doi: 10.1016/s0002-9270(99)00433-5
  12. Bozec A, Ruffion A, Decaussin M, Andre J, Devonec M, Benahmed M, Mauduit C. Activation of caspases-3, -6, and -9 during finasteride treatment of benign prostatic hyperplasia. Journal of Clinical Endocrinology & Metabolism. 2005;90(1):17-25. doi: 10.1210/jc.2004-0712
  13. Mrass P, Rendl M, Mildner M, Gruber F, Lengauer B, Ballaun C, Eckhart L, Tschachler E. Retinoic acid increases the expression of p53 and proapoptotic caspases and sensitizes keratinocytes to apoptosis: a possible explanation for tumor preventive action of retinoids. Cancer Research. 2004;64(18):6542-6548. doi: 10.1158/0008-5472.can-04-1129
  14. Livak KJ., Schmittgen TD. Analysis of relative gene expression data using Real-Time quantitative PCR and the 2—∆∆CT method. Methods. 2001;25(4):402-408. doi: 10.1006/meth.2001.1262
  15. Papa S, Bubici C, Zazzeroni F, Franzoso G. Mechanisms of liver disease: cross-talk between the NF-kappaB and JNK pathways. Biological Chemistry. 2009;390(10):965-976. doi: 10.1515/bc.2009.111
  16. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. Journal of Clinical Investigation. 1995;95(5):2409-2415. doi: 10.1172/jci117936
  17. Lesmana CR, Hasan I, Budihusodo U, Gani RA, Krisnuhoni E, Akbar N, Lesmana LA. Diagnostic value of a group of biochemical markers of liver fibrosis in patients with non-alcoholic steatohepatitis. Journal of Digestive Diseases. 2009;10(3):201-206. doi: 10.1111/j.1751-2980.2009.00386.x
  18. Zahran WE, Salah El-Dien KA, Kamel PG, El-Sawaby AS. Efficacy of Tumor Necrosis Factor and Interleukin-10 Analysis in the Follow-up of Nonalcoholic Fatty Liver Disease Progression. Indian Journal of Clinical Biochemistry. 2012;28(2):141-146. doi: 10.1007/s12291-012-0236-5
  19. Tsukamoto H. Is interleukin-10 antifibrogenic in chronic liver injury? Hepatology. 1998;28(6):1707-1709. doi: 10.1002/hep.510280635
  20. Yilmaz Y. Systematic review: caspasecleaved fragments of cytokeratin 18 (the promises and challenges of a biomarker for chronic liver disease. Alimentary Pharmacology & Therapeutics. 2009;30(11-12):1103-1109. doi: 10.1111/j.1365-2036.2009.04148.x
  21. Ribeiro PS, Cortez-Pinto H, Solá S, Castro RE, Ramalho RM, Baptista A, Moura MC, Camilo ME, Rodrigues CM. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. The American Journal of Gastroenterology. 2004;99(9):1708-1717. doi: 10.1111/j.1572-0241.2004.40009.x
  22. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. Journal of Clinical Investigation. 2004;(114):147-152. doi: 10.1172/jci200422422
  23. Negrin KA, Roth Flach RJ, DiStefano MT, Matevossian A, Friedline RH, Jung D, Kim JK, Czech MP. IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis. PLoS One. 2014;9(9):e107265. doi: 10.1371/journal.pone.0107265

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies